{
  "id": 4964838,
  "title": "Xeris Biopharma CFO Steven Pieper sells $42,500 in shares",
  "url": "https://urgent.news/2026/09/01/xeris-biopharma-cfo-steven-pieper-sells-42-500-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-01T23:30:55.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/xeris-biopharma-cfo-steven-pieper-sells-42500-in-shares-93CH-4884735"
  },
  "original_language": "en",
  "account": "On September 1, 2026, Xeris Biopharma Holdings, Inc.'s Chief Financial Officer Steven Pieper sold 5,000 shares of the company's common stock for a total of $42,500. The transaction was conducted under a Rule 10b5-1 trading plan adopted by Mr. Pieper on August 18, 2025. Currently, Mr. Pieper still holds 1,356,053 shares of Xeris Biopharma common stock. Xeris Biopharma shares have seen a 38% return over the past six months, according to InvestingPro data, but the current stock price of $8.43 may be considered overvalued by the platform. In their recent second-quarter 2026 financial results, Xeris Biopharma reported $92.1 million in revenue, surpassing analyst estimates, but also posted a loss of $0.18 per share, missing a projected profit of $0.01. The company's strong commercial momentum, driven by high demand for RECORLEV and rebounding sales of Gvoke, was noted, yet profitability challenges persist due to a one-time non-cash GAAP charge from convertible note remeasurement.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Indie semiconductor COO Wittmann sells $63,400 in stock",
        "url": "https://urgent.news/2026/09/01/indie-semiconductor-coo-wittmann-sells-63-400-in-stock",
        "published": "2026-09-01T23:21:39.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}